ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Injectable BMSC-Based Extracellular Matrix-Mimicking Microtissue for Myocardial Infarction Repair.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A randomized, open, two-period, cross-over, single oral dose, pharmacokinetics and bioequivalence study of vitamin KFrontiers in pharmacology · 2026Trial
- Myocardial infarction treatment with a composite hydrogel containing metformin-induced vesicles of adipose-derived stem cells.Materials today. Bio · 2026Article
- Silk-Fibroin-Based Strategies for Myocardial Infarction Repair: A Comprehensive Review.International journal of molecular sciences · 2026Review
- M1 macrophage-derived migrasomes exacerbate post-myocardial infarction injury via guanylate binding protein 5.Journal of nanobiotechnology · 2026Article
- Distribution-based covariate assessment using wasserstein distance in population pharmacokinetic models.Frontiers in pharmacology · 2026Article
- Integrative computational approach to elucidate the efficacy of cordyceps in managing lupus nephritis: from molecular targets to clinical applications.Frontiers in medicine · 2026Article
- Ginsenoside Rg3 promotes chemosensitivity in lung adenocarcinoma organoids via apoptotic pathways.Frontiers in pharmacology · 2026Article
- Effects of herbal medicines and their phytoconstituents on vagus nerve stimulation: a systematic review ofFrontiers in pharmacology · 2026Review
- Mitochondria-targeted nanotechnology in cardiovascular diseases: a review of recent advances.Regenerative biomaterials · 2026Review
- Injectable BMSC-Based Extracellular Matrix-Mimicking Microtissue for Myocardial Infarction Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Biomimetic astragaloside-IV-loaded mesoporous silica nanoparticles for treatment of dilated cardiomyopathy.Frontiers in pharmacology · 2026Article
- SGLT-2 inhibitors improve cardiac function in hypertrophic cardiomyopathy: a real-world propensity score-matched study.Frontiers in cardiovascular medicine · 2026Article
- Beyond blood pressure: the renin-angiotensin system as an innovative driver and therapeutic target in pathological scarring.Frontiers in pharmacology · 2026Review
- Activation of BK channels ameliorates cardiac injury Via NFκB-NLRP3 signaling in angiotensin II-induced hypertension mouse model.Frontiers in pharmacology · 2026Article
- Senkyunolide I and Danshensu in combination ameliorate post-MI myocardial fibrosis by regulatingFrontiers in pharmacology · 2026Article
- Exosome-mediated cell-cell communication: a new perspective on the mechanisms and therapeutic potential of diabetic microvascular complications.Frontiers in pharmacology · 2026Review
- Urinary miR-142-3p: a novel biomarker of the progression of IgA nephropathy.Frontiers in immunology · 2026Article
- Janus base nanotubes-driven biomimetic microenvironments for enhanced 3D cell spheroid development and extracellular matrix production.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
After myocardial infarction, the myocardial microenvironment is altered by cardiomyocyte loss, inflammation, and extracellular matrix degradation, creating a hostile environment that severely limits bone marrow-derived mesenchymal stem cell (BMSC) survival, migration, and differentiation. The BMSCs may differentiate into cardiomyocyte-like cells in vitro. However, this potential remains significantly limited in vivo because of the lack of supportive signals and conducive microenvironments. To overcome these challenges, this study presents a novel injectable biomimetic microtissue system containing a dual biomimetic extracellular matrix scaffold consisting of Janus Basic Nanotubes, laminin, stromal-derived factor-1 alpha, and vascular endothelial growth factor (JLSV) for BMSC delivery (JLSV-BMSC microtissue) designed to mimic the natural myocardial microenvironment. In vitro experiments showed that the microtissue enhanced BMSC survival, proliferation, migration, anti-apoptotic capacity, and paracrine signaling under oxygen-glucose deprivation conditions. In vivo studies have shown that the microtissue significantly improves BMSC retention at the infarct site, directs their differentiation into cardiomyocytes and endothelial cells, reduces myocardial fibrosis and apoptosis, and promotes angiogenesis, contributing to improved cardiac remodeling and functional recovery. These results suggest that the JLSV-BMSC microtissue is a promising therapeutic strategy for myocardial infarction that addresses the critical challenges of stem cell-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.